Ser Hooi-Leng, Tan Wen-Si, Mutalib Nurul-Syakima Ab, Yin Wai-Fong, Chan Kok-Gan, Goh Bey-Hing, Lee Learn-Han
Monash University Malaysia, School of Pharmacy, Novel Bacteria and Drug Discovery Research Group (NBDD), Selangor Darul Ehsan, Malaysia; Monash University Malaysia, Jeffrey Cheah School of Medicine and Health Sciences, Biomedical Research Laboratory, Selangor Darul Ehsan, Malaysia; Monash University Malaysia, School of Pharmacy, Biofunctional Molecule Exploratory Research Group (BMEX), Bandar Sunway, Malaysia.
University of Malaya, Faculty of Science, Institute of Biological Sciences, Division of Genetics and Molecular Biology, Malaysia.
Braz J Microbiol. 2018 Apr-Jun;49(2):207-209. doi: 10.1016/j.bjm.2017.04.012. Epub 2018 Feb 2.
Streptomycetes remain as one of the important sources for bioactive products. Isolated from the mangrove forest, Streptomyces gilvigriseus MUSC 26 was previously characterised as a novel streptomycete. The high quality draft genome of MUSC 26 contained 5,213,277bp with G+C content of 73.0%. Through genome mining, several gene clusters associated with secondary metabolites production were revealed in the genome of MUSC 26. These findings call for further investigations into the potential exploitation of the strain for production of pharmaceutically important compounds.
链霉菌仍然是生物活性产品的重要来源之一。从红树林中分离出来的吉尔维灰链霉菌MUSC 26先前被鉴定为一种新型链霉菌。MUSC 26的高质量草图基因组包含5,213,277bp，G+C含量为73.0%。通过基因组挖掘，在MUSC 26的基因组中发现了几个与次级代谢产物产生相关的基因簇。这些发现呼吁对该菌株在生产药学上重要化合物方面的潜在开发进行进一步研究。
